Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PMN310 · 1 trial · 1 indication
Number and severity of adverse events
Mean change in plasma p-tau217 in response to repeat intravenous infusions of PMN310
| Arm | Type | Description |
|---|---|---|
| Cohort 1 PMN310 350 mg or placebo | EXPERIMENTAL | PMN310 350 mg or placebo administered as a 60-minute infusion. |
| Cohort 2 PMN310 700 mg or placebo | EXPERIMENTAL | PMN310 700 mg or placebo administered as a 60-minute infusion. |
| Cohort 3 PMN310 1400 mg or placebo | EXPERIMENTAL | PMN310 1400 mg or placebo administered as a 60-minute infusion. |
| Name | Type | Description |
|---|---|---|
| PMN310 | DRUG | A humanized immunoglobulin G1 (IgG1) monoclonal antibody |
| Placebo | DRUG | 0.9% NaCl 100 mL |
Inclusion Criteria: 1. Patient and caregiver provide written informed consent. 2. Ambulatory male or female ≥ 50 years of age with adequate visual and auditory abilities to perform the cognitive and functional assessments in the opinion of the Investigator. 3. Meets all of the following clinical cr...
PMN310 is an investigational small molecule being developed by ProMIS Neurosciences Inc. for early onset Alzheimer disease. It is designed to target amyloid-beta oligomers and is currently in Phase 1 clinical development. It has received Fast Track designation from the FDA.
PMN310 is being studied as a treatment for early onset Alzheimer disease. It is an investigational therapy in Phase 1 testing and has not been approved for any indication. The Phase 1 trial enrolls patients aged 50 years and older with early Alzheimer disease.
PMN310 targets amyloid-beta oligomers. It is a small molecule designed to bind these oligomers, which are considered a toxic form of amyloid-beta in Alzheimer disease. This targeted approach distinguishes it from therapies aimed at amyloid plaques.
PMN310 is being developed by ProMIS Neurosciences Inc., a biotechnology company whose common stock trades under the ticker symbol PMN. The company is advancing the drug as its lead candidate for early Alzheimer disease.
PMN310 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is active but not recruiting, and the program has received FDA Fast Track designation.
PMN310 is being evaluated in the Phase 1 PRECISE-AD trial, registered as NCT06750432. The trial is titled PMN310 in Patients With Early Alzheimer's Disease and is active but not recruiting. It is a randomized, double-blind, controlled study with a planned enrollment of 144 participants in the United States.